NOT FOR PUBLICATION

STRICTLY PRIVATE & CONFIDENTIAL

Our clients: the Mortimer Sackler Family

In the Matter of: Purdue Pharma and the US Opioid Crisis Litigation

We are instructed by the Mortimer Sackler Family, this being Dame Theresa Sackler and the late Mortimer
Sackler’s children and their respective families.

You will be aware that a settlement announcement has been made today in respect of the Oklahoma claim
made against Purdue Pharma in the US Opioid Litigation. It will be known to you that Purdue Pharma is
one of the defendants to the action.

You will be aware of significant coverage of the family and the involvement of certain family members in
litigation in the US. For the avoidance of doubt, the Sackler family have never been defendants in the
Oklahoma claim. The settlement does not amount to an acceptance of responsibility by the family
for the opioid crisis in the US, nor is it expressly or impliedly an admission of any wrong-doing on
their part.

We do not attempt to suggest for one moment that the US opioid crisis or the issue of opioid addiction in
the UK are not legitimate matters of public interest, and that it is perfectly open to news outlets to cover
them. It is also fully accepted that the media are perfectly within its rights to report fairly and accurately on
the proceedings in the US and any settlement of them.

However, the topic is nonetheless controversial, and the public interest is in fact undermined and ill-served
when the reporting on the subject is false, distorted and/or misleading. It is correct to say that there have
been substantial amounts of coverage which has contained significant misleading or inaccurate claims in
relation to the US litigation and the opioid crisis more generally.

Yesterday we had cause to write to the BBC about the highly misleading interview given by Nan Goldin to
the Today programme in which numerous claims were made, none of which have any truth. Giving an
individual with an obvious agenda unfettered air time without any counter-balance and impartiality allows
the public to be misled and the public interest undermined.

Telephone: +44 (0)20 3375 7000 Email: media@farrer.co.uk Web: www.farrer.co.uk

For the avoidance of doubt the correct key facts are:

• OxyContin represents a very small percentage of the overall opioid prescriptions issued in the US (it
has never been more than 4%);

• OxyContin is a Food and Drugs Administration (FDA)1 approved prescription drug, meaning it is
safe and effective for its intended uses. OxyContin is available only by prescription, meaning that a
patient can obtain it only after a healthcare provider has determined that it is appropriate for him or
her;

• The FDA has always been aware that there is a risk of OxyContin abuse, which is why the label
carried an appropriate warning and the drug has always been a Schedule II drug (meaning that it
has a high potential for abuse). It is for healthcare providers to make decisions about whether
OxyContin or any other drug is appropriate for an individual patient;

In addition, we are also aware of:

• Death threats to a member of the family;

• An individual going through a family member’s bins (we have the photographic evidence);
• A journalist intruder at Dame Theresa’s Berkshire home; and
• Online anti-Semitic comments directed at the Sackler family.

In these circumstances, we would wish that the reporting on the US Litigation and the opioid crisis more
generally will more accurately reflect the facts and that pejorative language and exaggerated claims will be
avoided.

Should you have any questions about the content of this notice, please contact us. If journalists require to
speak with anyone, they should contact Antony Dunkels or Jo Sheldon at Edelman PR.

Antony Dunkels – antony.dunkels@edelman.com

Jo Sheldon – jo.sheldon@edelman.com

Julian Pike, Partner,

Farrer & Co LLP

Julian.Pike@farrer.co.uk

020 3375 7217 or 07790 911 857

1 The FDA is the US food and drugs regulator

Telephone: +44 (0)20 3375 7000 Email: media@farrer.co.uk Web: www.farrer.co.uk